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 Introduction 
 Pancreatic cancer (PC) is a dismal disease associated 
with a poor prognosis and a 5-year survival rate <10% for 
all stages, despite multimodal therapy  [1] . The main fac-
tors for the lethal outcome are not only that most patients 
suffer from a primarily locally unresectable tumor or with 
metastatic disease at the time of diagnosis, but that many 
candidates for surgery do not benefit from a R0 resection 
 [1] . A subgroup of these patients, who might benefit from 
locoregional therapies, are those with unresectable local-
ly advanced PC (LAPC).
 LAPC is characterized by the absence of distant metas-
tases combined with complex tumor surrounding vessels, 
which either drastically complicates the resection or 
makes the resection approach impossible. According to 
the most common definitions, LAPC can be divided into 
borderline resectable (<10% of PC) and unresectable 
stages (20–30% of PC)  [1, 2] . Whereas reported median 
survival reaches approximately 18 months for borderline 
resectable LAPC, unresectable LAPC shows reduced sur-
vival expectations of 9–13 months  [3] . The heterogeneous 
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 With the advent of novel and somewhat effective chemo-
therapy against pancreas cancer, several groups developed 
a new interest on locally advanced pancreatic cancer (LAPC). 
Unresectable tumors constitute up to 80% of pancreatic can-
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definitions of LAPC prevent any conclusive comparisons 
among different groups. The most popular classification 
systems are the American Hepato-Pancreato-Biliary As-
sociation (AHPBA)  [4] , the National Comprehensive 
Cancer Network (NCCN) guidelines  [5] and MD Ander-
son  [6] classification ( table 1 ). The AHPBA classification 
is based on the extent of the tumor-vascular involvement 
and the NCCN guidelines adopted this classification pro-
viding a definition of LAPC based on radiological char-
acteristics describing the tumor-surrounding vessel in-
volvement  [7] . In contrast, the MD Anderson classifica-
tion extended the criteria of vessel involvement to 
patient-related characteristics. This system results in 3 
classification subgroups as follows: Group A – radiologi-
cal tumor arterial abutment or encasement or short-seg-
ment occlusion of the superior mesenteric vein (SMV), 
portal vein (PV) or PV-SMV; Group B – lesions sugges-
tive for metastases; Group C – comorbidities requiring 
further workup and performance status of the patient  [8] .
 High diagnostic accuracy is mandatory for proper 
therapeutic decision-making and distinction between re-
sectable, borderline resectable and unresectable tumors. 
The diagnostic armamentarium includes contrast-en-
hanced CT, MRI, transcutaneous and endoscopic ultra-
sound (EUS)  [9] . Multiphase contrast-enhanced CT en-
ables 3-dimensional reconstruction of the pancreas and 
associated vascular structures. A histological analysis 
should be obtained by EUS-guided fine-needle biopsy  [7] . 
In selected cases, diagnostic laparoscopy or laparotomy is 
used to exclude peritoneal metastases.
 The current standard of care for unresectable LAPC is 
limited to chemotherapy alone or combined with chemo-
radiotherapy. Initial reports about gemcitabine mono-
therapy  [10] or combination therapy  [11] for unresect-
able LAPC provided disappointing response rates in the 
vicinity of 10%, whereas latter studies using gemcitabine-
based combination regimes revealed higher response 
rates of approximately 25%  [12–15] . This positive evolu-
tion in response rates, however, did not significantly 
translate into improved survival; median survival re-
mained poor (<10 months)  [13, 16] . Furthermore, en-
couraging results of the PRODIGE trial in 2011  [17] 
opened the door for the folinic acid, fluorouracil, irinote-
can, oxaliplatin (FOLFIRINOX) regime, as a new effec-
tive chemotherapeutic strategy for metastatic or unre-
sectable LAPC. Of importance, convincing trials investi-
gating the efficacy of FOLFIRINOX in unresectable LAPC 
patients are missing up to date. Only retrospective analy-
ses and a review of the literature postulate response rates 
between 35 and 40% with disease control rates of over 
80%  [18–21] .
 Several chemoradiotherapy combinations have been 
investigated as a treatment option for unresectable LAPC. 
Patients treated with gemcitabine-based chemoradiation 
protocols showed median survival from 11 to 15 months 
 [22, 23] . The recent SCALOP study reported a survival 
benefit for orally administered 5-FU (capecitabine) based 
chemoradiation regimen, as compared with gemcitabine 
plus radiation (15 vs. 13 months, p = 0.012)  [24] . Future 
perspectives for unresectable LAPC include a combina-
tion of FOLFIRINOX and radiation. Although evidence 
is anecdotal, initial reports postulate the feasibility of this 
approach  [25, 26] .
 Despite the aforementioned advances in chemothera-
py and chemoradiotherapy regimen, LAPC remains a 
disease with dismal prognosis. Locoregional ablative 
strategies for LAPC, delivered either intraoperatively, 
percutaneously or through EUS guidance, have evolved 
Table 1.  LAPC concept
Borderline resectable [4, 5] Unresectable LAPC [4, 5]
Absence of distant metastases
Involvement of SMV or PV
No encasement of nearby arteries
Proximal and distally free vessel
Involvement of SMV or PV
Unreconstructable vein occlusion
Gastroduodenal artery encasement
No extension to the celiac axis
Encasement of celiac artery >180°
Encasement of SMA <180° Encasement of SMA >180°
Local lymph node metastases Distant lymph nodes metastases
 SMA = Superior mesenteric artery.
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on the knowledge gathered with tumors arising in other 
organs, which are routinely treated with these techniques.
 A heterogeneous armamentarium of locoregional ab-
lative therapeutic options has been described for unre-
sectable solid organ malignancies. Liver tumors are an 
example where ablative strategies have been safely used 
for a long time. The pancreas, however, entails the risk of 
complications of associating injuries, especially the duo-
denum and major vessels. This led to delayed implemen-
tation of ablative techniques in LAPC with improving re-
sults over time. Local ablation was shown to palliate ther-
apy-resistant pain and prolong survival by locally 
controlling the tumor burden as an additive to chemo or 
chemoradiotherapy. According to the energy applied, 
thermal- and non-thermal ablative techniques can be dis-
tinguished  [27, 28] . This review mainly focuses on the 
role of ablative treatment in LAPC patients with emphasis 
on non-thermal ablation.
 Ablation Therapy for LAPC 
 Thermal Ablation 
 Radiofrequency Ablation 
 Radiofrequency ablation (RFA) is the most common 
thermal ablation therapy used for LAPC. This approach 
is typically performed intraoperatively, with very little ex-
perience percutaneously. Briefly, radiofrequency causes 
tissue destruction by using heat (usually >40   °   C) gener-
ated from high frequency alternating current and exerts 
its effect via coagulation and protein denaturation  [29, 
30] .
 Although suggesting a survival benefit in up to 20 
months  [31] compared to 13 months in patients receiving 
standard chemotherapy alone, this treatment inherently 
entails the risk of thermal injuries to adjacent structures 
and pancreatic fistulae. Initial experiences translating this 
technique from animal studies into human revealed a 
morbidity rate up to 40%  [32] . In the study by Wu et al. 
 [33] , the mortality rate reached 25%, whereas 3 quarters 
of these patients died from massive gastrointestinal hem-
orrhage after pancreatic head tumor ablation. Other cen-
ters demonstrated a wide range of mortality and morbid-
ity rates  [34–36] down to 3% mortality and 15% RFA-
related morbidity  [37] ( table 2 ). Overall, PV thrombosis 
is the most frequent complication (15%) while duodenal 
injury seems to be the most threatening complication 
(8%)  [37] . These injuries can range from asymptomatic 
mucosal burns to penetrating ulcers with massive bleed-
ing requiring immediate surgical treatment. Girelli et al. 
 [37] reported in 2013 the technical tips for improving 
RFA outcomes in LAPC: (a) avoiding temperatures over 
90  °  C and (b) preventing high temperatures to diffuse to 
healthy surrounding tissues by not ablating the total tu-
mor volume. These aspects may allow creating a ‘safety 
margin’ for temperature-associated tissue destruction. 
When such considerations were applied, the results shift-
ed to lower complication rates (15%) and a progression-
free survival rate of 22% at a median follow-up of 12 
months  [37] ( fig. 1 ). A most recent study showed safety 
and feasibility of RFA under EUS guidance in 22 patients. 
The median post-ablation survival time was 6 months. 
Except one patient suffering from minor gastrointestinal 
bleeding not requiring further treatment, complications 
were related only to tumor progression  [38] .
 Chemotherapy alone or combined chemoradiothera-
py has an important role in the treatment of LAPC; how-
ever, there is currently little evidence to give recommen-
dations on how to combine ablation therapy with chemo-
therapy or chemoradiation. For example, Girelli et al.  [37] 
presented a retrospective study with 100 pancreatic RFA 
ablations in the context of a multimodal approach ( fig. 1 ). 
In this study, the majority of cases (48%) were treated first 
by RFA followed by chemoradiotherapy, 29% received 
different chemotherapy regimen prior to RFA with 
chemoradiotherapy after ablation, 17% received chemo-
radiotherapy before and after RFA and 6% underwent 
different approaches, including intra-arterial chemother-
apy, overall resulting in a median disease-free survival of 
23 months  [37] . Evidence regarding whether chemother-
apy alone or chemoradiation should be offered before 
RFA, after RFA or both is still insufficient, and new study 
protocols are necessary to address these questions.
 Microwave Ablation 
 Microwave (MW) ablation is performed by a genera-
tor using MW energy via an antenna to induce tissue 
heating of the area of interest. Major difference between 
MW ablation and RFA is the frequency range of the elec-
tromagnetic waves resulting in a better predictable abla-
tion volume  [39] . MW ablation results in coagulative tis-
sue necrosis and is an established ablative method for 
unresectable malignant liver tumors. However, the expe-
rience of MW ablation for unresectable LAPC is limited. 
The largest case series  [40] comprises 15 patients in 
which all partial necrosis was achieved with no major 
procedure-related morbidity or mortality. The longest 
patient follow-up was 22 months  [40, 41] . Despite en-
couraging results, MW ablation for LAPC as well as its 
efficacy together with chemoradiotherapy is under in-
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vestigation without any conclusive data currently avail-
able regarding indication and best ablation protocol for 
LAPC.
 Cryoablation 
 Cryoablation was first described in a primate model in 
the 1970s  [42] and was thereafter used for other tumor 
entities as hepatocellular carcinoma before the indication 
for PC ablation  [43] . This procedure cools the tumor un-
til ice ball formation occurs, leading then to tumor necro-
sis. Ideally, this ice ball engulfs and destroys the tumor 
while sparing healthy tissue. Cryoablation for LAPC is 
reported mostly in retrospective case series. This therapy 
presents complication rates ranging from 0 to 40%  [44, 
 45] having the most severe bleeding from the puncture 
site or cracking of the liver, pancreatitis and overall sur-
Table 2.  RFA outcome in LAPC
Year Author Indication Study n Mode Primary 
outcome
Results Complications
2013 Giardino et al. 
[34]
LAPC Retrospective 
observational
107 Intraoperative OS RFA: 14.7 months
RFA + CRT: 25.6 
months
Mortality: 1.8%
Morbidity: 28%
2013 Figueroa-Barojas 
et al. [35]
LAPC Retrospective 
observational
57 Intraoperative OS
DFS
OS and DSS:
19 months
Mortality: 0%
Morbidity: 3.5%
2013 Girelli et al. 
[37]
LAPC Prospective 
cohort
100 Intraoperative OS
PFS at 1 year
OS at 1 year: 41%
PFS at 1 year: 22%
Mortality: 3%
Morbidity: 24%
2012 Arcidiacono 
et al. [38]
LAPC Prospective 
cohort
22 EUS guided Safety
Feasibility
Feasible: 72.8% Pain: 13.6%
2010 Girelli et al. 
[32]
LAPC Prospective 
cohort
50 Intraoperative Safety
Feasibility
– Morbidity: 24%
2007 Spiliotis et al. 
[31]
LAPC, 
stage IV
Retrospective 
observational
16 Intraoperative OS OS: 33 months Mortality: 0%
Morbidity: 16%
2006 Wu et al. [33] LAPC Retrospective 
observational
16 Intraoperative Pain relief 50% pain relief Mortality: 25%
Pancreatic 
fistula: 18.8%
2000 Matsui et al. 
[36]
LAPC, 
stage IV
Restrospective 
observational
29 Intraoperative OS OS: 3 months Mortality: 10%
 DFS = Disease-free survival; PFS = progression-free survival; CRT = chemoradiotherapy.
RFA* CRT48
CT CRTRFA*29
CRT CRTRFA*17
CRT + intra-arterial CT CRTRFA*6
Patients (%) Treatment type Survival
41% overall survival
Median overall survival: 20 months
Median disease free survival: 23 months
22% progression free survival
 Fig. 1. RFA treatment for LAPC. CT = Che-
motherapy; CRT = chemoradiotherapy. 
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vival (OS) rates between 12 and 30 months  [45, 46] . Cur-
rently, this type of ablation technique seems to be aban-
doned for LAPC.
 High Intensity Focused Ultrasound 
 High intensity focused ultrasound (HIFU) is an emerg-
ing ultrasound (US)-based system causing thermal tissue 
destruction, when boiling bubbles disrupt the tissue me-
chanically  [47] . High amplitude pressure waves focused 
on very small regions exert this effect thereby sparing the 
intervening tissue. This highly focused therapy requires 
high resolution imaging techniques, essentially diagnostic 
US or MRI to safely guide HIFU. A recent study on HIFU 
in stages III and IV PC included 30 patients achieving a 
partial treatment response in 4 patients and local disease 
control in 22 patients. Adverse events occurred in 10% of 
the cases as pancreatic pseudocyst formation and mild 
pancreatitis. New developments include, for example, 
miniaturized HIFU capable for minimally invasive HIFU 
ablation, either laparoscopically or percutaneously  [48] .
 In summary, thermal ablation therapy aims to relieve 
pain and prolong survival via local tumor control. These 
various techniques do have unique advantages and disad-
vantages making them more or less suitable in different 
situations  [49] . However, the best treatment modality, as 
well as the sequential combination with chemotherapy 
and chemoradiotherapy, was investigated only in small, 
non-randomized clinical studies, keeping the question 
open as to how to improve survival rates in unresectable 
LAPC-treated by thermal ablation.
 Non-Thermal Ablation – IRE 
 Irreversible electroporation (IRE) is a new non-ther-
mal ablation technique which has been recently used for 
LAPC  [50] . Electroporation was introduced in the late 
1950s with the demonstration that electric stimulation 
causes cell membrane disruption. This observation was 
further developed and later introduced in cancer therapy 
as reversible electroporation  [51] . Then, reversible elec-
troporation was initially used to enhance chemotherapy 
uptake in tumors by membrane permeabilization  [52] . 
Afterwards, higher magnitude electric pulses caused ir-
reversible nanopores in the cell membrane and conse-
quently cell death  [50, 53] ( fig. 2 ). Importantly, this effect 
shows a molecular selectivity by only affecting the lipid 
bilayer of the cell membrane whereas thermal ablation 
techniques affect all molecules in the treated area  [51] .
 IRE works when energy is applied by placing at least 2 
needles (maximum 6) around the tumor tissue. Pulses of 
direct current (maximum 50 ampere) are delivered for 70 
μs between the needles. For safety reasons, this delivery 
rate is synchronized to the heart rate (ECG triggered) re-
sulting in one energy pulse per R-wave. Potential hazards 
when dealing with IRE are electrical harmonics that can 
cause cardiac arrhythmias or muscle contraction. There-
fore IRE treatment can only be performed under general 
anesthesia and paralytic induction.
 Major drawback inherent to all thermal ablation tech-
niques is the fact that these therapies comprise the risk of 
heat-sink effect. This becomes particularly important, as 
the pancreas is an organ with a peculiar position, with 
 Fig. 2. Electroporation effects on the cellular membrane. This figure was adopted from Bower et al.  [53] . 
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close relation to the duodenum, the bile duct and major 
vessels. This feature turned IRE into an attractive tool for 
LAPC ablation. Taking together that pathological studies 
revealed that a third of patients died of PC as a result of 
local tumor infiltration, without evidence for metastatic 
disease  [54] , this population appears to be ideal for IRE to 
increase patient survival and, importantly, quality of life.
 A prospective, multi-institutional study included 54 
patients comparing standard regimen of chemotherapy 
or chemoradiation with IRE  [55] . Only patients with PC 
AJCC stage III criteria for LAPC were included in the 
study (70% primary of the pancreatic head, 30% primary 
of the pancreatic body). Ninety percent of the patients 
received chemotherapy or chemoradiation pre-IRE, 
while 10% received this treatment after IRE. Comparing 
this cohort to patients receiving standard treatment, an 
improvement of local progression-free survival (14 vs. 
6  months), distant progression-free survival (15 vs. 
9 months) and OS (20 vs. 13 months) was reported ( fig. 3 ). 
Complications in the IRE group included bile leaks and 
duodenal leaks, 4% each, with 1 patient dying within 90 
days after intervention. This study suggests a possible 
benefit in LAPC patient survival, when IRE is combined 
with chemotherapy and/or chemoradiation.
 A registry-based study showed high rate of complica-
tions (42%) post-IRE for PC. However, only 19% were 
related to the procedure itself and with incomplete abla-
tion in 2 cases. Another important point demonstrated in 
this study is the correlation of the learning curve to the 
rate of complications, which seems to drop after a cumu-
lative experience of minimal 5 IRE cases in PC  [56] .
 Among the small series of a percutaneous approach for 
IRE  [57, 58] , pancreatitis and pneumothorax were the 
most frequent complications, while the 6 months OS rate 
ranged from 40 to 70% ( table 3 ). These studies focused 
mostly on feasibility and safety. However, longer follow-
up is necessary to evaluate local recurrence rate using per-
cutaneous IRE.
 In addition to that, IRE has been described as a tool to 
increase the number of negative margins after pancre-
atectomy in borderline resectable PC, especially regard-
ing the retroperitoneal margin  [59] . Forty-eight patients 
eligible for resection were enrolled in this study, 25 bor-
derline resectable and 23 LAPC. All patients underwent 
chemoradiotherapy according to local regimen before 
and after resection. Only 6% experienced local recurrence 
with a median survival of 22.4 months. Within 90 days, 
adverse events occurred in 38% of patients with 11% pos-
sibly related to IRE. Taking this together, margin accen-
tuation by IRE is a new concept, which requires further 
investigation.
 In our center, IRE for unresectable LAPC is indicated 
for tumors up to 4 cm in the anterior-posterior axis. De-
spite controversies, biliary metal stent or other material 
in the vicinity of the IRE ablation has been adopted as 
contraindication to perform IRE in LAPC. It is per-
formed following induction chemotherapy and in the 
absence of metastases. Those patients undergo diagnos-
tic laparoscopy at the time of the procedure and depend-
ing on individual indication, associated surgical proce-
dures as choledocojejunostomy and gastrojejunostomy 
may be performed. This therapy was firstly applied by 
90 pulses delivery, and most recently, modulated pulse 
delivery (meaning repeated sequence of fewer pulses) is 
preferred. All patients undergo chemotherapy after IRE 
treatment, and only in presence of local recurrence they 
undergo radiotherapy. Despite the procedure seeming 
to be safe, there are unknown important points regard-
C-RT IRE C-RT90
IRE C-RT10
1
2 CRT100
Patients (%) Treatment type Survival
Time
Local progression free survival: 14 months
Distant progression free survival: 15 months
Overall survival: 20 months
Local progression free survival: 6 months
Distant progression free survival: 9 months
Overall survival: 13 months
 Fig. 3. Treatment approaches using IRE 
and chemoradiotherapy. C-RT = Chemo/
chemoradiotherapy; CRT  = chemoradio-
therapy. 
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ing the use of chemo or chemoradiotherapy, patient se-
lection, type of imaging for follow-up and assessment of 
treatment success. Therefore, critical evaluation of IRE 
results is mandatory for better management of LAPC 
patients.
 Image-Guided Percutaneous Ablation 
 Although percutaneous US- or CT-guided biopsy and 
fine needle aspiration of pancreatic lesions were estab-
lished procedures for some time, percutaneous ablation 
of pancreatic tumors was perceived as neither feasible nor 
safe until recently. Indeed, in the vast majority of patients 
with LAPC reported hitherto, the applicators were insert-
ed under US guidance intraoperatively ( tables 2 and  3 ). 
Pancreas anatomical constraints may limit percutaneous 
applicator placement, while this may not be an issue at 
open approach. For instance, the presence of peri-pancre-
atic varices  [57] or the lack of an US ‘window’ represents 
limitations to the percutaneous approach. On one hand, 
the open approach allows confirmation of tumor inoper-
ability. On the other hand, a postoperative ‘hostile’ anat-
omy or severe comorbidity may be a reason to favor the 
less invasive percutaneous access. In 2 small series, the 
feasibility and safety of percutaneous US- or CT-guided 
percutaneous IRE has been shown  [57,  58] . In a report of 
5 patients, there were no immediate complications after 
percutaneous US-guided MW ablation performed with 
moderate sedation  [41] . A single late complication, a 
pseudoaneurysm of the gastroduodenal artery, occurred 
after 1 month  [41] . The published clinical experience in 
ablation for LAPC does not give us any hint yet regarding 
the choice of the ablative method, the best approach 
(open vs. percutaneous) or the type of imaging guidance. 
However, as techniques evolve continuously, percutane-
ous ablation therapy for LAPC may gain wider accep-
tance.
 Conclusion 
 Ablative techniques for unresectable LAPC are a rap-
idly emerging field focusing on local tumor control. Cur-
rently, long-term data or randomized controlled trials are 
not available yet for any of the mentioned ablative treat-
ments. In addition, the role of ablation therapy combined 
with chemotherapy or chemoradiotherapy, and the best 
therapy sequence is unclear. Most clinical ablative experi-
ence for LAPC exists with RFA. However, the high rate of 
complications of RFA for LAPC seems to be an important 
drawback. Conversely, IRE is gaining acceptance, pro-
ceeding fast from the experimental stage to clinical prac-
tice, but convincing data about effectiveness of IRE has 
not been published yet and a randomized control trial 
comparing IRE with standard therapy seems timely. 
Therefore, better survival rates in LAPC may be accom-
plished in the future by individualized patient treatment 
in a multidisciplinary approach with new emerging ther-
apies. 
Table 3.  IRE outcome in LAPC
Year Author Indication Study n Mode Primary 
outcome
Results Complications
2014 Mansson 
et al. [58]
LAPC Phase 1 5 Percutaneous
US-guided
Safety 6 months survival: 40%
30 days mortality: 0
Pancreatitis 
(n = 1)
2013 Philips 
et al. [56]
LAPC Retrospective
observational
59 Intraoperative Safety – Morbidity: 42%
2013 Martin 
et al. [55]
LAPC Prospective 
cohort
54 Intraoperative OS
PFS
OS for IRE and CT/RT: 20 
months
PFS for IRE and CT/RT: 15 
months
OS for CT/RT: 13 months
PFS for CT/RT: 6 months
Morbidity in IRE 
and CT/RT: 22%
Morbidity in CT/
RT: 41%
2012 Narayanan 
et al. [57]
LAPC, 
stage IV
Retrospective 
observational
14 Percutaneous
US-guided
Safety 6-month OS: 70% Pancreatitis (n = 1)
Pneumothorax 
(n = 1)
 CT = Chemotherapy; RT = radiotherapy; PFS = progression-free survival.
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